285PDBalixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial. (23rd October 2018) - Cortes Castan, J; Martín, M; Pernas Simon, S; Gomez Pardo, P; Lopez-Tarruella, S; Gil Martin, M; Manso, L M; Ciruelos, E M; Perez Fidalgo, J A; Hernando, C; Ademuyiwa, F; Weilbaecher, K; et al.